 This study is a comparative, double blind, placebo controlled trial of 6-months duration designed to evaluate 1 the effects of fluoxetine in 5 to 12 years old autistic children, 2 the effects of fluoxetine on serotoninergic parameters, 3 cerebral metabolic changes rCBF measurements with PET induced by the treatment. 